Legend Biotech Results Presentation Deck
5
Q3 2023 Performance
CARVYKTIⓇ NET SALES ($MM)
U.S.
EU
Global
Q3 2023
Q3 2023
$96
YTD 2023
$206
140
12
152
TOTAL REVENUE ($MM)
Q/Q
Change
23%
300%
30%
Q3 2022
$27
YTD 2022
$89
Y/Y Change
155%
N/A
176%
Y/Y Change
251%
Y/Y Change
130%
This presentation is for investor relations purposes only - Not for product promotional purposes
EPS ($)
Q3 2023
-0.17
YTD 2023
-1.07
Q3 2022
-0.26
YTD 2022
-0.99
Y/Y Change
-35%
Y/Y Change
8%
Q3 2023 and Recent Highlights
→ Entered into an exclusive, global license agreement with Novartis, which grants
Novartis the rights to develop, manufacture and commercialize LB2102 and other
potential CAR-T therapies selectively targeting DLL3
a) To receive an upfront payment of $100M and eligible to receive up to $1.01B
in milestone payments, as well as tiered royalties on net sales.
b) To be reimbursed for development costs for the ongoing Phase 1 clinical trial
→ 1st patient enrolled for CARTITUDE-6
→ One of our Ghent facilities to begin clinical supply manufacturing, pending approvals
of the Investigational Medicinal Product Dossier by local authorities
→ Cash and cash equivalents, time deposits, and short-term inves ments of $1.4 billion;
which we believe will fund operating and capital expenditures through 2025
LEGEND
BIOTECHView entire presentation